Headquartered in London, England, Concordia International Corp.("Concordia" or the Company) is a diverse, international pharmaceutical company focused on legacy medicines and orphan drugs.

According to the law firm press release, the Complaint charges Concordia and certain of its officers with violations of the federal securities laws. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose: (1) that the Company was experiencing a substantial increase in market competition against the Company’s drug, Donnatal, and other products; (2) that, as a result, the Company’s financial results would suffer, and the Company would be forced to suspend its dividend; and (3) that, as a result of the foregoing, Defendants’ statements about Concordia’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis.

On November 8, 2016, the Court appointed Lead Plaintiff and Counsel. On December 8, Lead Plaintiff filed an amended Complaint. On July 28, 2017, the Court granted in part and denied in part Defendants' Motion to Dismiss.

On February 7, 2018, Lead Plaintiff filed a Motion to Certify a Class in this action. On July 27, the Court issued an Order denying the Motion to Certify a Class.

On May 23, 2018, the Court issued an Order granting Plaintiff's motion to replace Lead Plaintiff.

On December 20, 2018, the parties entered into a Stipulation and Agreement of Settlement. The Court issued an Order granting preliminary approval of the Settlement on February 28, 2019. On September 10, the Court granted final approval of the Settlement and entered Final Judgment.